• Contact
  • Press And News

Womens Health


Candida albicans, significant decrease.

Trial 129: Verification of the decrease of Candida albicans in the gastrointestinal tract of healthy subjects, after supplementation of the lactic yeast Kluyveromyces marxianus fragilis B0399, through

Candida albicans: Kluyveromyces B0399 direct inhibitory activity

Trial 96: In vitro test on the effect of the typified lactic yeast (Kluyveromyces marxianus B0399) on the development of Candida albicans ATCC10231. Authors: Dr. Tiziana Cettolo, Dr. Lorena Riul &nd

Probiotic Lactic Yeast ® Kluyveromyces B0399: immune system stimulation, gut colonization, bifidobogenic effect and other strain specific, probiotic properties

Trial 143: Potential probiotic Kluyveromyces marxianus fragilis B0399 modulates the immune response in Caco-2 cells and PBMCs and impacts on the human gut microbiota in an in vitro colonic model syste
2024. © All rights reserved. Laboratori Turval Italia srl (TURVAL Laboratories Ltd.) - Head Office and Research Dpt: Friuli innovazione (AREA international Science Park-TS), Via Linussio 51-33100 Udine (IT) – P. IVA 01883020305
We use cookies to enhance your browsing experience. If you want to disable cookies, please set your browser.